The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies
Top Cited Papers
Open Access
- 14 January 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 669
Abstract
Glioblastoma (GBM) is an aggressive brain tumor characterized by extensive metabolic reprogramming that drives tumor growth and therapeutic resistance. Key metabolic pathways, including glycolysis, lactate production, and lipid metabolism, are upregulated to sustain tumor survival in the hypoxic and nutrient-deprived tumor microenvironment (TME), while glutamine and tryptophan metabolism further contribute to the aggressive phenotype of GBM. These metabolic alterations impair immune cell function, leading to exhaustion and stress in CD8+ and CD4+ T cells while favoring immunosuppressive populations such as regulatory T cells (Tregs) and M2-like macrophages. Recent studies emphasize the role of slow-cycling GBM cells (SCCs), lipid-laden macrophages, and tumor-associated astrocytes (TAAs) in reshaping GBM’s metabolic landscape and reinforcing immune evasion. Genetic mutations, including Isocitrate Dehydrogenase (IDH) mutations, Epidermal Growth Factor Receptor (EGFR) amplification, and Phosphotase and Tensin Homolog (PTEN) loss, further drive metabolic reprogramming and offer potential targets for therapy. Understanding the relationship between GBM metabolism and immune suppression is critical for overcoming therapeutic resistance. This review focuses on the role of metabolic rewiring in GBM, its impact on the immune microenvironment, and the potential of combining metabolic targeting with immunotherapy to improve clinical outcomes for GBM patients.Keywords
Funding Information
- Singapore Ministry of Health’s National Medical Research Council (MOH-000560, AM/SU086/2023)
- SingHealth Duke-NUS Academic Medicine Research Grant (MOH-000560, AM/SU086/2023)
This publication has 213 references indexed in Scilit:
- Tumor‐Selective Nano‐Dispatcher Enforced Cancer Immunotherapeutic Effects via Regulating Lactate Metabolism and Activating Toll‐Like ReceptorsSmall, 2024
- Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastomaCancer Communications, 2023
- PERK‐Mediated Cholesterol Excretion from IDH Mutant Glioma Determines Anti‐Tumoral Polarization of MicrogliaAdvanced Science, 2023
- Recruiting T‐Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co‐Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage‐Membrane‐Camouflaged NanovesiclesAdvanced Materials, 2023
- Insights into the Effect of Catalytic Intratumoral Lactate Depletion on Metabolic Reprogramming and Immune Activation for Antitumoral ActivityAdvanced Science, 2022
- Insights in the immunobiology of glioblastomaJournal of Molecular Medicine, 2019
- Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastomaCancer Immunology, Immunotherapy, 2019
- Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomasInternational Journal of Cancer, 2009
- Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapyCancer Immunology, Immunotherapy, 2007
- Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human gliomaInternational Journal of Cancer, 2000